DDInter38 DDInter624
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Amprenavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Efavirenz
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Cinoxacin {u} (Compound) causes {v} (Side Effect) Somnolence
Somnolence {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Efavirenz (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Efavirenz (Compound)